International Journal of Molecular Sciences (Aug 2023)

Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

  • Joao Carlos Batista-Liz,
  • Vanesa Calvo-Río,
  • María Sebastián Mora-Gil,
  • Belén Sevilla-Pérez,
  • Ana Márquez,
  • María Teresa Leonardo,
  • Ana Peñalba,
  • Francisco David Carmona,
  • Javier Narvaez,
  • Luis Martín-Penagos,
  • Lara Belmar-Vega,
  • Cristina Gómez-Fernández,
  • Luis Caminal-Montero,
  • Paz Collado,
  • Patricia Quiroga-Colina,
  • Miren Uriarte-Ecenarro,
  • Esteban Rubio,
  • Manuel León Luque,
  • Juan María Blanco-Madrigal,
  • Eva Galíndez-Agirregoikoa,
  • Javier Martín,
  • Santos Castañeda,
  • Miguel Angel González-Gay,
  • Ricardo Blanco,
  • Verónica Pulito-Cueto,
  • Raquel López-Mejías

DOI
https://doi.org/10.3390/ijms241713063
Journal volume & issue
Vol. 24, no. 17
p. 13063

Abstract

Read online

ITGAM–ITGAX (rs11150612, rs11574637), VAV3 rs17019602, CARD9 rs4077515, DEFA (rs2738048, rs10086568), and HORMAD2 rs2412971 are mucosal immune defence polymorphisms, that have an impact on IgA production, described as risk loci for IgA nephropathy (IgAN). Since IgAN and Immunoglobulin-A vasculitis (IgAV) share molecular mechanisms, with the aberrant deposit of IgA1 being the main pathophysiologic feature of both entities, we assessed the potential influence of the seven abovementioned polymorphisms on IgAV pathogenesis. These seven variants were genotyped in 381 Caucasian IgAV patients and 997 matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of these seven polymorphisms when the whole cohort of IgAV patients and those with nephritis were compared to controls. Similar genotype and allele frequencies of all polymorphisms were disclosed when IgAV patients were stratified according to the age at disease onset or the presence/absence of gastrointestinal or renal manifestations. Likewise, no ITGAM–ITGAX and DEFA haplotype differences were observed when the whole cohort of IgAV patients, along with those with nephritis and controls, as well as IgAV patients, stratified according to the abovementioned clinical characteristics, were compared. Our results suggest that mucosal immune defence polymorphisms do not represent novel genetic risk factors for IgAV pathogenesis.

Keywords